Growth-hormone axis · Peptide
GHRP-6
An early growth-hormone-releasing peptide that also strongly stimulates appetite.
Status as of 2026-07 · reclassification ≠ FDA approval · educational only, not medical advice.
The signal it sends
Ghrelin-receptor agonist driving GH release and hunger signaling.
Benefits & effects studied
- GH release
- Marked appetite increase
- Gut-motility research
Research state
Older research peptide; not approved.
Dosing & pharmacokinetics
Several times daily in protocols. Half-life: Short.
Dosing information is educational only. GHRP-6 decisions belong with a licensed clinician — Jevity does not recommend or supply dosing.
History & discovery
First described 1984 by Cyril Y. Bowers (with chemist Frank Momany) Origin: Arose from Cyril Bowers' observation in the late 1970s that chemically modified enkephalins released growth hormone without opioid effects; over years of structure-activity work with Frank Momany, he developed GHRP-6, characterized in 1984 as the first synthetic peptide to specifically release GH. Bowers predicted an unknown natural ligand, later found as ghrelin in 1999..
Molecular structure
A synthetic six-amino-acid peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) acting on the growth hormone secretagogue receptor.
Frequently asked questions
Is GHRP-6 FDA-approved?
Not FDA-approved — research use only On Jevity's evidence scale, GHRP-6 is graded "Early / limited human data". Reclassification for compounding is not the same as FDA approval.
What is GHRP-6 used for?
An early growth-hormone-releasing peptide that also strongly stimulates appetite. Ghrelin-receptor agonist driving GH release and hunger signaling. Studied effects include: GH release; Marked appetite increase; Gut-motility research. This is educational information, not a recommendation to use it.
Is GHRP-6 legal in the UAE?
UAE / DHA status: Prescription-only via a DHA-licensed clinic
Is GHRP-6 banned in sport?
WADA status: Prohibited at all times (GH axis)
What is GHRP-6's Jevity Score?
GHRP-6 has a Jevity Score of 37/100 — a proprietary composite of evidence strength (4/10), regulatory clarity (3/10) and supply verifiability (4/10). It reflects how established and legitimate the compound is, not a recommendation.
GHRP-6 is prescription-only or research-only. A licensed clinician must evaluate whether it's appropriate for you.
Book a consult →Related growth-hormone axis peptides
Educational information only — not medical advice, a diagnosis, or a recommendation to use any substance or therapy. Regulatory status changes; verify current rules and any personal decision with a licensed clinician. Jevity is operated by Upcapital Global FZCO, Dubai, UAE.